GeneDx announced on September 30, 2025, the appointment of Lisa Gurry as Chief Business Officer (CBO), effective immediately. This newly created executive role is designed to lead GeneDx’s next phase of transformation by advancing data and information services across biopharma, health systems, and other partners.
As CBO, Ms. Gurry will be responsible for architecting and operating strategic business operations and partnership models to unlock the full potential of GeneDx Infinity™. This proprietary dataset, comprising nearly one million exomes and genomes paired with over seven million phenotypic datapoints, is a key asset for accelerating drug discovery and development.
Ms. Gurry brings deep expertise from her role as co-founder of Truveta and over two decades at Microsoft, where she drove global growth strategies. Her leadership is expected to drive value and improve patient outcomes by delivering genomic insights across various healthcare sectors, further solidifying GeneDx's position in precision medicine.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.